Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients.